Get started
NeuroMetrix, Inc.NeuroMetrix, Inc.NeuroMetrix, Inc.

NeuroMetrix, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

NURO trade ideas

risky NURO recent change of direction due to potential catalyst With recent move above downward trendlines and brief sideway action pre split, a confirmed uptrend began with channel from break out price near 3.20 coupled with upper channel formation from prior low. This gave green light for short term trade toward prior high points near 4.78. After initial break out the low band of channel began to form and price has continued along this short term high angle uptrend. Trend reversal target of 8.50 can be confirmed using point and figure analysis, along the way there are several pivot points with 0.80 cent and above 1.00 intervals. With first target already made will watch for 4.78 to act as support in price before heading back up toward higher targets. Watching this low float set up and follow through realizing this is a binary news event stock whereby the next announcement will either confirm stock holder equity that has been valued with funds from selling parts of the company and /or merger announcement to offset the shortage of cash for future operations or incur a rapid sell off from a new equity offering that dilutes current share prices.
NASDAQ:NUROLong
by DrRAV
Intermediate to short term 'Gap Coverage' Analysis; All watch as Neuro attempts to cover it's previous earnings gap to the downside. As you can see we have a polarity between indicators, with stochastics saying 'down boy' and the previous Fibonacci ratio of .786 that was obeyed implying a rise to atleast 100% of the previous fall to around 1.35-1.40 should eventually happen. If we can't break 1.10 though today I feel we could drop into the .90-1.10 channel to build up more volume for the next try. Stochastics have crossed though but then intraday has entered a phase of being overbought.
NASDAQ:NUROLong
by candlestickninja
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it. Increased quarterly earnings growth. Low floater Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83 Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
NASDAQ:NURO
by alipipefitter
1